OakChart

Oculis Holding AG

OCSHealthcare·Biotechnology·Switzerland·Small·NASD·Nov 10 • 3:59 PM ET

7.590.00 (0.00%)
2026-11-11 14:54 CET
Market cap
468.55 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-101.30 USD m
Free cash flow, TTM
-87.18 USD m
EPS diluted, TTM
-1.72
P/E
-
Compare

Price

OCS against its 20, 50 and 200-day averages
2050200beatmiss
10.0020.0030.003.3M6.7MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26OCSclose 7.5920-day 7.6550-day 9.01200-day 18.177.59

78.0% under 34.48 on 11 May 2026. Last 15 sessions, 30.4% high to low

Profile

OCS
52-week range, 3% of the way up
6.7834.47

Oculis Holding AG is a global biopharmaceutical company, which engages in sight and improving eye care. The firm's pipeline includes multiple product candidates in development such as, OCS-01, a topical retinal candidate for diabetic macular edema, OCS-02, a topical biologic candidate for dry eye disease, and OCS-05, a disease modifying candidate for acute optic neuritis and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company was founded in 2016 and is headquartered in Zug, Switzerland.

Employees60
IPOMay 18, 2021
Beta0.30
ATR, 14d0.60
Rel volume0.00
Short float3.37%
Insider own23.77%
Inst own25.78%

Snapshot

6 groups

Valuation

Index-
Market Cap468.55M
Enterprise Value220.03M
Income-101.30M
Sales0.00M
Book/sh4.04
Cash/sh4.08
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees60
IPOMay 18, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B1.88
P/C1.86
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio10.41
Current Ratio10.41
Debt/Eq0.01
LT Debt/Eq0.01
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.72
EPS next Y-1.89
EPS next Q-0.51
EPS this Y24.40%
EPS next Y-8.99%
EPS next 5Y5.51%
EPS past 3/5Y-26.82% -
Sales past 3/5Y- -
EPS Y/Y TTM31.72%
Sales Y/Y TTM-
EPS Q/Q9.72%
Sales Q/Q-
EarningsNov 03 AMC
EPS/Sales Surpr.23.35% -97.88%

Ownership

Insider Own23.77%
Insider Trans0.00%
Inst Own25.78%
Inst Trans8.93%
ROA-41.42%
ROE-48.92%
ROIC-40.14%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-0.84%
SMA50-15.79%
SMA200-58.23%
Trades-

Technical

Shs Outstand61.92M
Shs Float47.06M
Short Float3.37%
Short Ratio5.98
Short Interest1.58M
52W High34.47 -77.98%
52W Low6.78 11.95%
Volatility11.61% 7.76%
ATR (14)0.60
RSI (14)42.93
Beta0.30
Rel Volume0.00
Avg Volume264.63K
Volume0

Performance

Perf Week-0.52%
Perf Month-3.68%
Perf Quarter-41.12%
Perf Half Y-75.04%
Perf YTD-61.99%
Perf Year-60.92%
Perf 3Y-22.55%
Perf 5Y-21.99%
Perf 10Y-
Recom1.27
Target Price36.66
Prev Close7.59
Price7.59
Change %0.00%

Analyst ratings

latest 10 of 10
DateActionAnalystRating changeTargetImplied
May 21, 2026InitiatedGGuggenheimBuy$75+888.1%
Dec 19, 2025InitiatedJJP MorganOverweight$38+400.7%
Aug 27, 2025InitiatedNNeedhamBuy$36+374.3%
Dec 05, 2023InitiatedCChardan Capital MarketsBuy$30+295.3%
Oct 05, 2023InitiatedSStifelBuy$35+361.1%
Jun 14, 2023InitiatedBBofA SecuritiesBuy$22+189.9%
Jun 12, 2023InitiatedHH.C. WainwrightBuy$28+268.9%
Jun 08, 2023InitiatedRRobert W. BairdOutperform$58+664.2%
May 10, 2023InitiatedPParetoBuy$23+203.0%
Apr 28, 2023InitiatedWWedbushOutperform$27+255.7%

Peers

Mkt cap
TickerCompanyMkt cap
EYPTEyePoint Inc34.31M
OCULOcular Therapeutix Inc1.46B
KODKodiak Sciences Inc6.79B
TARSTarsus Pharmaceuticals Inc3.64B
ALDXAldeyra Therapeutics Inc38.62M
LENZLENZ Therapeutics Inc127.25M
REGNRegeneron Pharmaceuticals Inc92.98B
HROWHarrow Inc1.15B
BLCOBausch + Lomb Corp7.67B
GKOSGlaukos Corp14.08B

Insider trading

1 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Sherif RiadOfficerMar 09 '26Proposed Sale26.4025,000660,000Mar 09 04:08 PM

Held by

AUM
TickerCompanyAUM
SBIOALPS Medical Breakthroughs ETFAUM: 192.80M
GWXState Street SPDR S&P International Small Cap ETFAUM: 897.36M
ONEQFidelity Nasdaq Composite Index ETFAUM: 10.41B
BBCVirtus Biotech Clinical Trials ETFAUM: 31.57M
GLCRGlacierShares Nasdaq Iceland ETFAUM: 1.41M

News

latest 14 of 206
  • Oculis to Host In-Person and Virtual R&D Day: Advancing a Differentiated Late-Stage Development Pipeline (GlobeNewswire)
  • Oculis Reports Q3 2026 Financial Results and Builds Momentum Toward Multiple Upcoming Pipeline Catalysts (GlobeNewswire)
  • Oculis Appoints Experienced Life Sciences Leader Bjorn Tackenberg, M.D., Ph.D., as Chief Scientific Officer to Advance Neurology Innovation (GlobeNewswire) -6.66%
  • Oculis to Feature Privosegtor's Neuroprotective Potential and Ongoing PIONEER Program at APOIS Congress and CNS Summit (GlobeNewswire)
  • Oculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor's Neuroprotective Potential in Optic Neuritis (GlobeNewswire)
  • Loading…
  • Oculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS Meeting (GlobeNewswire)
  • Oculis lýkur slembiroðun i PREDICT-1 skraningarrannsokninni a Licaminlimab við TNFR1-miðluðum augnþurrki (GlobeNewswire)
  • Oculis Completes Randomization in PREDICT-1 Registrational Trial of Licaminlimab for TNFR1-Mediated Dry Eye Disease (GlobeNewswire)
  • Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities (GlobeNewswire)
  • Oculis to Highlight Licaminlimab at Eyecelerator @ AAO 2026 and Partner with Neuro-Ophthalmology Subspecialty Day (GlobeNewswire)
  • Oculis Joins the National Multiple Sclerosis Society's Campaign to End MS (GlobeNewswire) -6.21%
  • Oculis Announces Resignation of Lionel Carnot from Board of Directors (GlobeNewswire)
  • Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-03-0.366-0.478-0.3660.010.2610
2026Q22026-08-06-0.197-0.479-0.2060.370.2210
2026Q12026-05-11-0.630-0.512-0.6250.220.269
2025Q42026-03-03-0.537-0.497-0.5260.530.159
2025Q32025-11-10-0.397-0.512-0.4020.300.208
2025Q22025-08-21-0.606-0.508-0.5870.340.251
2025Q12025-05-08-0.830-0.524-0.7660.340.217
2024Q42025-03-11-0.758-0.524-0.7640.000.237
2024Q32024-11-07-0.548-0.553-0.5570.240.286
2024Q22024-08-27-0.602-0.488-0.5680.290.295
2024Q12024-05-08-0.485-0.413-0.5030.240.296
2023Q42024-03-18-0.385-0.464-0.3840.210.277
2023Q32023-11-15-0.536-0.363-0.5420.210.127
2023Q22023-08-29-0.430-0.296-0.4270.200.204
2023Q12023-08-17-0.320--0.2880.20-2
2022Q42023-04-270.000--0.00--

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2022FY-13.775--1.1180.96-
2023FY-1.856-3.431-3.3051.001.00
2024FY-2.400-2.078-2.4110.781.01
2025FY-2.417-2.316-2.2661.531.04
2026FY--1.732--0.96
2027FY--1.888--4.10
2028FY--1.933--20.92
2029FY--1.892--117.18
2030FY--0.183--351.33

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-048320.300.000.61
2026Q4S2026-11-038200.260.000.45
2026Q4S2026-11-028200.260.000.45
2026Q4S2026-10-308110.210.000.45
2026Q4S2026-10-277100.240.000.45
2026Q4S2026-10-217200.240.000.45
2026Q4S2026-10-077220.240.000.44
2026Q4S2026-09-258220.250.000.45
2026Q4S2026-08-158220.260.000.45
2026Q4S2026-08-138320.260.000.46
2026Q4S2026-08-128230.200.000.37
2026Q4S2026-08-078220.360.001.23
2026Q4S2026-07-308110.390.001.23
2026Q4S2026-07-299110.380.001.22

Estimate history

EPS, annual0.108-1.118-3.305-2.411-2.281-1.7196
Period20212022202320242025TTM
EPS, quarterly-0.557-0.764-0.766-0.587-0.402-0.526-0.625-0.206-0.363
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual000000
Period20212022202320242025TTM
Sales, quarterly000000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual16.39936.23336.6543.66257.98461.92
Period20212022202320242025MRQ
Shares, quarterly41.94543.66252.06154.53452.37557.98460.38861.73261.92
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY
Total Revenue0.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.760.660.460.320.310.00
Gross Profit-0.76-0.66-0.46-0.32-0.310.00
Selling, General and Administrative Excl. Other112.8999.1383.4451.6934.541.10
Research and Development71.9968.3358.8332.3023.03-
Other Operating Expense0.000.000.000.000.000.00
Operating Income-113.64-99.79-83.90-52.00-34.85-1.10
Interest Expense1.371.000.731.466.750.00
Unusual Expense-4.9614.8017.6442.610.00-2.58
Net Income Before Taxes-101.70-119.38-97.58-98.70-40.461.48
Income Taxes-0.40-0.22-0.180.120.060.00
Consolidated Net Income-101.30-119.16-97.40-98.82-40.521.48
Net Income From Continuing Operations-101.30-119.16-97.40-98.82-40.521.48
Net Income-101.30-119.16-97.40-98.82-40.521.48
EPS (Recurring)-1.69-2.08-2.10-2.31-1.12-0.02
EPS (Basic, Before Extraordinaries)-1.72-2.28-2.41-3.31-1.120.11
EPS (Diluted)-1.72-2.28-2.41-3.31-1.120.11
EBITDA-112.89-99.13-83.44-51.69-34.54-1.10
Non-Operating Income (Expense)8.36-3.794.68-2.621.140.00
Other After Tax Adjustments0.000.000.000.000.000.00
Stock Option Compensation Expense-15.468.773.010.67-
Price To Earnings Ratio---123.81123.81-
Shares Outstanding61.9257.9843.6636.6536.2316.40
Market Capitalization468.55468.55692.67408.63408.63-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.330.230.200.000.190.140.140.14
Gross Profit-0.33-0.23-0.200.00-0.19-0.14-0.14-0.14
Selling, General and Administrative Excl. Other28.7829.9927.8026.3325.4825.3022.4019.54
Research and Development18.3519.2017.8116.6317.5717.9316.3513.32
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-29.11-30.21-27.99-26.33-25.67-25.43-22.54-19.68
Interest Expense0.460.390.220.300.200.220.270.28
Unusual Expense-3.89-15.3110.194.05-3.860.2813.2515.26
Net Income Before Taxes-22.50-12.61-36.94-29.65-21.05-30.72-36.94-32.93
Income Taxes-0.050.01-0.13-0.230.02-0.030.01-0.27
Consolidated Net Income-22.45-12.61-36.82-29.42-21.06-30.69-36.95-32.66
Net Income From Continuing Operations-22.45-12.61-36.82-29.42-21.06-30.69-36.95-32.66
Net Income-22.45-12.61-36.82-29.42-21.06-30.69-36.95-32.66
EPS (Recurring)-0.41-0.38-0.50-0.47-0.45-0.58-0.57-0.51
EPS (Basic, Before Extraordinaries)-0.36-0.21-0.62-0.53-0.40-0.59-0.77-0.76
EPS (Diluted)-0.36-0.21-0.62-0.53-0.40-0.59-0.77-0.76
EBITDA-28.78-29.99-27.80-26.33-25.48-25.30-22.40-19.54
Non-Operating Income (Expense)3.182.691.461.030.96-4.78-0.882.28
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense11.036.244.74-4.237.902.172.11
Shares Outstanding61.9261.7360.3957.9852.3754.5352.0643.66
Market Capitalization468.55792.941,520.141,141.67958.701,058.50913.44692.67

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY
Cash & Short Term Investments268.87108.87108.8921.390.87
Short Term Receivables2.261.671.431.170.00
Inventories0.000.000.000.000.00
Other Current Assets5.155.219.703.020.05
Total Current Assets276.29115.75120.0225.570.92
Net Property, Plant & Equipment3.781.861.241.210.00
Total Investments and Advances0.000.000.000.05127.56
Intangible Assets16.7814.6714.5013.190.00
Deferred Tax Assets---0.03-
Other Assets0.990.530.110.000.00
Total Assets297.84132.80135.8740.06128.47
Short Term Debt Incl. Current Port. of LT Debt0.630.350.210.150.00
Accounts Payable2.276.489.034.180.06
Other Current Liabilities43.4841.9913.458.660.45
Total Current Liabilities46.3848.8122.6812.990.51
Long Term Debt2.290.950.51132.880.00
Provision for Risks Charges1.692.060.860.100.00
Other Liabilities0.000.000.450.007.11
Total Liabilities50.3551.8324.51145.977.61
Non-Equity Reserves0.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.00
Common Equity247.4980.97111.36-105.91120.86
Total Shareholders Equity247.4980.97111.36-105.91120.86
Accumulated Minority Interest0.000.000.000.000.00
Total Equity247.4980.97111.36-105.91120.86
Total Liabilities & Stockholders Equity297.84132.80135.8740.06128.47
Book Value Per Share4.271.853.04-2.927.37
Tangible Book Value Per Share3.981.522.64-3.297.37
Full-Time Employees604936282
Price to Book Ratio1.886.32-0.46-0.46-
Return on Assets-55.34-72.51-112.34-48.09-
Return on Equity-72.55-101.28-3,627.05-542.13-
Return on Invested Capital-47.71-118.88-88.33-150.261.22
Quick Ratio5.962.375.291.971.81
Current Ratio5.962.375.291.971.81

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY
Net Income-100.51-119.38-97.58-98.70-40.461.48
Depreciation0.950.660.460.320.31-
Other Funds (Non Cash)18.3840.3627.1152.927.61-2.55
Funds from Operations-81.19-78.36-70.02-45.46-32.53-1.07
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-5.92-0.0916.08-14.466.280.39
Cash from Operating Activities-87.11-78.45-53.94-59.92-26.25-0.69
Capital Expenditures-0.07-1.67-0.26-0.05-3.710.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-55.96-73.19-19.67-60.270.000.00
Purchase of Investments-55.96-73.19-19.67-60.270.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-56.03-74.87-19.94-60.32-3.710.00
Cash Dividends Paid0.000.000.000.000.000.00
Change in Capital Stock164.46225.6261.66144.470.060.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock164.46225.6261.66144.470.060.00
Proceedsfrom Stock Options159.45199.4557.51142.460.060.00
Issuance or Reduction of Debt, Net-0.000.000.000.000.00
Change in Long Term Debt-0.000.000.00-0.00
Issuance of Long Term Debt-0.000.000.00-0.00
Reduction of Long Term Debt--0.000.00-0.00
Net Financing Active Other Cash Flow0.000.000.000.001.90129.10
Other Financing Activities Uses0.000.000.000.00-0.22-2.99
Cash from Financing Activities163.77225.1861.35144.301.79129.10
Exchange Rate Effect3.93-7.300.46-3.420.44-
Net Change in Cash24.5664.57-12.0620.63-27.74128.42
Free Cash Flow-87.18-78.81-54.20-59.97-26.32-0.69
Preferred Dividends (Cash Flow)-0.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments251.86283.05276.32268.87182.47201.38
Short Term Receivables2.302.291.962.262.911.48
Inventories0.000.000.000.000.000.00
Other Current Assets3.133.594.265.154.295.93
Total Current Assets257.29288.93282.54276.29189.67208.79
Net Property, Plant & Equipment3.863.883.573.783.902.01
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets15.9216.4816.5416.7816.7116.70
Other Assets1.171.050.990.990.670.67
Total Assets278.24310.34303.64297.84210.94228.17
Short Term Debt Incl. Current Port. of LT Debt0.960.930.520.630.530.39
Accounts Payable1.733.335.602.271.531.51
Other Current Liabilities22.0330.3648.4743.4840.3344.01
Total Current Liabilities24.7334.6254.5946.3842.3945.91
Long Term Debt2.372.222.282.292.570.90
Provision for Risks Charges1.121.592.051.691.851.58
Other Liabilities0.000.000.000.000.000.00
Total Liabilities28.2238.4358.9250.3546.8148.40
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity250.02271.91244.72247.49164.13179.77
Total Shareholders Equity250.02271.91244.72247.49164.13179.77
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity250.02271.91244.72247.49164.13179.77
Total Liabilities & Stockholders Equity278.24310.34303.64297.84210.94228.17
Book Value Per Share4.044.404.054.273.133.30
Tangible Book Value Per Share3.784.143.783.982.812.99
Full-Time Employees---60--
Price to Book Ratio1.883.426.236.375.335.50
Return on Assets-41.42-37.11-44.16-54.86-67.45-64.62
Return on Equity-48.92-44.24-55.07-71.92-87.61-80.96
Return on Invested Capital-8.90-4.60-14.91-11.78-12.63-16.99
Quick Ratio10.418.355.185.964.474.55
Current Ratio10.418.355.185.964.474.55

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-21.94-12.35-36.94-29.28-23.30-33.60
Depreciation0.330.220.200.200.200.15
Other Funds (Non Cash)2.25-8.8515.649.342.7012.95
Funds from Operations-19.36-20.98-21.11-19.74-20.40-20.50
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-3.07-4.151.72-0.412.55-1.52
Cash from Operating Activities-22.43-25.13-19.39-20.15-17.85-22.02
Capital Expenditures0.00-0.02-0.01-0.04-0.20-0.25
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments28.59-10.87-32.77-40.91-4.3926.10
Purchase of Investments28.59-10.87-32.77-40.91-4.3926.10
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities28.59-10.89-32.78-40.96-4.5925.85
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock-2.0531.7030.29104.522.2410.32
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock-2.0531.7030.29104.522.2410.32
Proceedsfrom Stock Options-2.7531.1328.05103.011.437.04
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.00---
Issuance of Long Term Debt0.000.000.00---
Reduction of Long Term Debt--0.00---
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities-2.3231.5430.16104.392.1010.22
Exchange Rate Effect2.410.900.620.00-0.36-5.83
Net Change in Cash6.24-3.58-21.3943.29-20.708.22
Free Cash Flow-22.43-25.15-19.40-20.20-18.01-22.17

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-303.37%1.6M47.1M258.37K
2026-10-153.80%1.8M47.1M265.21K
2026-09-303.66%1.8M48.4M264.14K
2026-09-153.98%1.6M39.0M313.31K
2026-08-314.19%1.5M35.6M577.83K
2026-08-144.10%1.5M35.6M661.99K
2026-07-313.94%1.5M37.0M684.53K
2026-07-154.06%1.5M37.0M735.34K
2026-06-303.20%1.2M37.0M694.37K
2026-06-152.98%1.1M37.0M631.24K
2026-05-291.76%0.7M37.0M425.83K
2026-05-151.35%0.5M37.0M370.89K
2026-04-301.23%0.4M36.3M354.34K
2026-04-151.14%0.4M37.5M320.34K
2026-03-311.34%0.5M35.4M330.47K
2026-03-131.38%0.5M35.4M306.42K
2026-02-271.76%0.6M35.4M234.11K
2026-02-131.07%0.4M35.4M204.22K
2026-01-300.96%0.3M35.8M175.75K
2026-01-150.96%0.3M35.8M127.03K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.503.007.500.0028.0910.000.000.933-0.0830.002
call5.000.654.909.009.3251.000.000.825-0.1120.003
call7.500.001.500.402.9676070.000.611-0.0770.005
call10.000.001.500.204.5074280.000.499-0.1140.005
call12.500.004.900.155.2247.000.000.456-0.1330.005
call15.000.001.000.033.3992700.000.202-0.0590.004
call17.500.004.900.055.63810.000.000.330-0.1300.005
call20.000.000.751.094.03215.000.000.129-0.0540.003
call22.500.004.9013.404.3544.000.000.123-0.0560.003
call25.000.004.901.024.4883.000.000.117-0.0560.003
call30.000.004.900.204.9507.000.000.110-0.0600.002
call35.000.004.901.185.3279.000.000.105-0.0620.002
call40.000.004.900.055.60514.000.000.101-0.0640.002
call45.000.004.900.005.8780.000.000.098-0.0660.002
put2.500.000.900.0010.1120.000.00-0.067-0.0830.002
put5.000.004.900.006.8660.000.00-0.175-0.1120.003
put7.500.001.550.003.2750.000.00-0.389-0.0760.005
put10.000.104.901.556.5490.000.00-0.501-0.1130.005
put12.502.507.002.426.6763.000.00-0.543-0.1360.005
put15.005.009.504.507.37928.000.00-0.653-0.1180.005
put17.507.5012.004.807.93210.000.00-0.670-0.1280.005
put20.0010.0014.506.108.3890.000.00-0.871-0.0520.003
put22.5012.5017.007.208.7756.000.00-0.877-0.0540.003
put25.0015.0019.506.009.1110.000.00-0.882-0.0550.002
put30.0020.0024.5020.009.6701.000.00-0.889-0.0580.002
put35.0025.0029.5021.9510.1250.000.00-0.894-0.0600.002
put40.0030.0034.5013.9010.5080.000.00-0.898-0.0610.002
put45.0035.5038.900.009.5980.000.00-0.900-0.0630.002

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-03424B5SEC
2026-11-036-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-30SEC
2026-09-306-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-30SEC
2026-08-106-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-10SEC
2026-08-06S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-066-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-30SEC
2026-06-256-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-25SEC
2026-06-016-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-29SEC
2026-05-146-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-14SEC
2026-05-116-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-03-31SEC
2026-04-29SCHEDULE 13G/ASEC
2026-04-216-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-21SEC
2026-03-27SCHEDULE 13G/ASEC
2026-03-09144Filing for proposed sale of securities under Rule 144.SEC
2026-03-046-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-03-04SEC
2026-03-04F-3ASRAutomatic shelf registration statement of securities of well-known seasoned issuersSEC
2026-03-0420-FRegistration statement under Section 12 of the Securities Exchange Act of 1934 or an annual or transition report filed under Section 13(a) or 15(d) of the Exchange Act for a foreign private issuer.2025-12-31SEC
2026-03-036-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-03-03SEC
2025-12-08EFFECTEffectiveness filing by commission orderSEC
2025-12-05POS AMPost-effective amendment to a registration statement that is not immediately effective upon filingSEC
2025-12-01424B3SEC
2025-11-14SCHEDULE 13G/ASEC
2025-11-10F-3Registration statement for specified transactions by certain foreign private issuersSEC
2025-11-106-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-11-10SEC
2025-10-31424B5SEC
2025-10-31424B5SEC
2025-10-316-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-10-31SEC
2025-10-296-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-10-29SEC
2025-10-09144Filing for proposed sale of securities under Rule 144.SEC
2025-10-066-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-10-06SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
EQT Fund Management S.a r.l.12.16%
Aberdeen Group plc3.70%
MILLENNIUM MANAGEMENT LLC3.57%
Pivotal bioVenture Partners Investment Advisor LLC2.63%
CITADEL ADVISORS LLC1.73%
BRAIDWELL LP1.46%
PERCEPTIVE ADVISORS LLC1.41%
Saturn V Capital Management LP1.20%
SR ONE CAPITAL MANAGEMENT, LP1.12%
Siren, L.L.C.1.09%

Funds

Fund% owned
abrdn Healthcare Investors1.27%
abrdn Healthcare Opportunities Fund1.20%
abrdn World Healthcare Fund0.73%
abrdn Life Sciences Investors0.57%
Franklin Biotechnology Discovery Fund0.55%
Global Macro Absolute Return Advantage Portfolio0.19%
THE HARTFORD HEALTHCARE FUND0.19%
VANGUARD INTERNATIONAL EXPLORER FUND0.18%
ALPS Medical Breakthroughs ETF0.12%
THE HARTFORD SMALL COMPANY FUND0.12%

OakChart. OCS. Cached 15 minutes.